pp-262 Tablets
Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Psychiatric disorder, Major depressive disorder, Depression
Clinical stage: Phase 3
Modality: Small molecule
Mechanism & Target: CNS modulator
Route & form: Oral
Differentiation: This is a first–in–class triple reuptake inhibitor that simultaneously targets the serotonin, norepinephrine and dopamine transporters.
Manufacturer #39676
A late-stage clinical biopharmaceutical company focused on unmet medical needs. Developing a small molecule therapeutic targeting unmet medical needs with global development focus. Pipeline positioned for regulatory advancement in key markets.
None